Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

C. Perelló, J. A. Carrión, B. Ruiz-Antorán, J. Crespo, J. Turnes, J. Llaneras, S. Lens, M. Delgado, J. García-Samaniego, F. García-Paredes, I. Fernández, R. M. Morillas, D. Rincón, J. C. Porres, M. Prieto, M. Lázaro Ríos, C. Fernández-Rodríguez, J. A. Hermo, M. Rodríguez, J. I. HerreroP. Ruiz, J. R. Fernández, M. Macías, J. M. Pascasio, J. M. Moreno, M. Serra, J. Arenas, Y. Real, F. Jorquera, J. L. Calleja, Federico Sáez Rayuela, Miguel ángel Simón, José Manuel González, Eduardo Muñoz, Marta González, Miguel Jiménez, Senador Moran, Mercè Vergara-Gómez, Felipe Jiménez, Rosa García, Alicia Hernández Albujar, José María Navarro, María Dolores Antón, Àngels Vilella, Lander Hijona, Fernando Gil, Ildefonso Quiñones, Jose Luis Montero, Gloria Ceña, Juan de la Vega, Xavier Torras, Moisés Diago, Javier Ampuero, Sonia Pascual, Natividad Zaragoza, Xavier Xiol, Maria José Devesa, Carmen Garay, Pablo Bellot, Javier Moreno, Mercè Roget, Maria Rosario González Alonso, Mariano Gómez-Rubio, Marta Valbuena, Belén Piqueras, Cristina Monton, Luis Cortés, Carmen Comas, Manuel Puertas, Andrés Sansó, Antonio García-Herola, Ximo Primo, Pilar Griño Garcia-Pardo, Javier Pamplona, Tomás de Artaza

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection'. Together they form a unique fingerprint.

Medicine & Life Sciences